{"id":"prevnar-20","rwe":[],"tags":[],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":["Can be co-administered with influenza vaccine and COVID-19 vaccines","Immunosuppressive therapies may reduce immune response"],"commonSideEffects":[{"effect":"Irritability","drugRate":"91.3%","organSystem":"Psychiatric disorders","placeboRate":"","totalAtRisk":781,"totalAffected":713,"trialsReporting":1},{"effect":"Somnolence","drugRate":"87.2%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":781,"totalAffected":681,"trialsReporting":1},{"effect":"Administration site pain","drugRate":"74.5%","organSystem":"General disorders","placeboRate":"","totalAtRisk":781,"totalAffected":582,"trialsReporting":1},{"effect":"Hypophagia","drugRate":"69.5%","organSystem":"Metabolism and nutrition disorders","placeboRate":"","totalAtRisk":781,"totalAffected":543,"trialsReporting":1},{"effect":"Pyrexia","drugRate":"66.7%","organSystem":"General disorders","placeboRate":"","totalAtRisk":781,"totalAffected":521,"trialsReporting":1},{"effect":"Administration site induration","drugRate":"61.5%","organSystem":"General disorders","placeboRate":"","totalAtRisk":781,"totalAffected":480,"trialsReporting":1},{"effect":"Administration site erythema","drugRate":"58.9%","organSystem":"General disorders","placeboRate":"","totalAtRisk":781,"totalAffected":460,"trialsReporting":1},{"effect":"Crying","drugRate":"55.3%","organSystem":"General disorders","placeboRate":"","totalAtRisk":781,"totalAffected":432,"trialsReporting":1},{"effect":"Diarrhoea","drugRate":"42.8%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":781,"totalAffected":334,"trialsReporting":1},{"effect":"Administration site swelling","drugRate":"41.2%","organSystem":"General disorders","placeboRate":"","totalAtRisk":781,"totalAffected":322,"trialsReporting":1},{"effect":"Vomiting","drugRate":"40.6%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":781,"totalAffected":317,"trialsReporting":1},{"effect":"Rash","drugRate":"27.7%","organSystem":"Skin and subcutaneous tissue disorders","placeboRate":"","totalAtRisk":781,"totalAffected":216,"trialsReporting":1},{"effect":"Upper respiratory tract infection","drugRate":"16.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":781,"totalAffected":125,"trialsReporting":1},{"effect":"Teething","drugRate":"9.6%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":781,"totalAffected":75,"trialsReporting":1},{"effect":"Cough","drugRate":"6.5%","organSystem":"Respiratory, thoracic and mediastinal disorders","placeboRate":"","totalAtRisk":781,"totalAffected":51,"trialsReporting":1},{"effect":"Otitis media","drugRate":"6.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":781,"totalAffected":47,"trialsReporting":1},{"effect":"Nasopharyngitis","drugRate":"5.1%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":781,"totalAffected":40,"trialsReporting":1},{"effect":"Nasal congestion","drugRate":"5.0%","organSystem":"Respiratory, thoracic and mediastinal disorders","placeboRate":"","totalAtRisk":781,"totalAffected":39,"trialsReporting":1},{"effect":"Dermatitis diaper","drugRate":"4.9%","organSystem":"Skin and subcutaneous tissue disorders","placeboRate":"","totalAtRisk":781,"totalAffected":38,"trialsReporting":1},{"effect":"Otitis media acute","drugRate":"4.2%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":781,"totalAffected":33,"trialsReporting":1},{"effect":"Constipation","drugRate":"4.0%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":781,"totalAffected":31,"trialsReporting":1},{"effect":"Respiratory symptom","drugRate":"4.0%","organSystem":"Respiratory, thoracic and mediastinal disorders","placeboRate":"","totalAtRisk":781,"totalAffected":31,"trialsReporting":1},{"effect":"Bronchiolitis","drugRate":"3.8%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":781,"totalAffected":30,"trialsReporting":1},{"effect":"Rhinorrhoea","drugRate":"3.2%","organSystem":"Respiratory, thoracic and mediastinal disorders","placeboRate":"","totalAtRisk":781,"totalAffected":25,"trialsReporting":1},{"effect":"Croup infectious","drugRate":"3.1%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":781,"totalAffected":24,"trialsReporting":1},{"effect":"Lymphadenopathy","drugRate":"2.6%","organSystem":"Blood and lymphatic system disorders","placeboRate":"","totalAtRisk":781,"totalAffected":20,"trialsReporting":1},{"effect":"Conjunctivitis","drugRate":"2.2%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":781,"totalAffected":17,"trialsReporting":1},{"effect":"Viral upper respiratory tract infection","drugRate":"2.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":781,"totalAffected":16,"trialsReporting":1},{"effect":"Eczema","drugRate":"2.0%","organSystem":"Skin and subcutaneous tissue disorders","placeboRate":"","totalAtRisk":781,"totalAffected":16,"trialsReporting":1},{"effect":"Gastrooesophageal reflux disease","drugRate":"1.8%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":781,"totalAffected":14,"trialsReporting":1},{"effect":"Influenza","drugRate":"1.7%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":781,"totalAffected":13,"trialsReporting":1},{"effect":"Viral infection","drugRate":"1.7%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":781,"totalAffected":13,"trialsReporting":1},{"effect":"Candida nappy rash","drugRate":"1.3%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":781,"totalAffected":10,"trialsReporting":1},{"effect":"Ear pain","drugRate":"1.2%","organSystem":"Ear and labyrinth disorders","placeboRate":"","totalAtRisk":781,"totalAffected":9,"trialsReporting":1},{"effect":"Gastroenteritis viral","drugRate":"1.2%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":781,"totalAffected":9,"trialsReporting":1},{"effect":"Respiratory syncytial virus infection","drugRate":"1.2%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":781,"totalAffected":9,"trialsReporting":1},{"effect":"Dermatitis","drugRate":"1.2%","organSystem":"Skin and subcutaneous tissue disorders","placeboRate":"","totalAtRisk":781,"totalAffected":9,"trialsReporting":1},{"effect":"Gastroenteritis","drugRate":"1.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":781,"totalAffected":8,"trialsReporting":1},{"effect":"Dermatitis atopic","drugRate":"1.0%","organSystem":"Skin and subcutaneous tissue disorders","placeboRate":"","totalAtRisk":781,"totalAffected":8,"trialsReporting":1},{"effect":"Hand-foot-and-mouth disease","drugRate":"0.9%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":781,"totalAffected":7,"trialsReporting":1},{"effect":"Erythema","drugRate":"0.9%","organSystem":"Skin and subcutaneous tissue disorders","placeboRate":"","totalAtRisk":781,"totalAffected":7,"trialsReporting":1},{"effect":"Injection site bruising","drugRate":"0.8%","organSystem":"General disorders","placeboRate":"","totalAtRisk":781,"totalAffected":6,"trialsReporting":1},{"effect":"COVID-19","drugRate":"0.8%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":781,"totalAffected":6,"trialsReporting":1},{"effect":"Sinusitis","drugRate":"0.8%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":781,"totalAffected":6,"trialsReporting":1},{"effect":"Wheezing","drugRate":"0.8%","organSystem":"Respiratory, thoracic and mediastinal disorders","placeboRate":"","totalAtRisk":781,"totalAffected":6,"trialsReporting":1},{"effect":"Haematochezia","drugRate":"0.6%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":781,"totalAffected":5,"trialsReporting":1},{"effect":"Food allergy","drugRate":"0.6%","organSystem":"Immune system disorders","placeboRate":"","totalAtRisk":781,"totalAffected":5,"trialsReporting":1},{"effect":"Candida infection","drugRate":"0.6%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":781,"totalAffected":5,"trialsReporting":1},{"effect":"Oral candidiasis","drugRate":"0.6%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":781,"totalAffected":5,"trialsReporting":1},{"effect":"Pharyngitis","drugRate":"0.6%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":781,"totalAffected":5,"trialsReporting":1}],"contraindications":["Severe allergic reaction (anaphylaxis) to any component of the vaccine or to any diphtheria toxoid-containing vaccine"],"specialPopulations":{"Pregnancy":"No adequate data; administer only if clearly needed","Paediatric use":"Approved for infants and children 6 weeks to <18 years (US, 2023)","Renal impairment":"No dose adjustment required","Hepatic impairment":"No dose adjustment required"},"discontinuationRates":[],"seriousAdverseEvents":[{"event":"Bronchiolitis","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.5%"},{"event":"Gastroenteritis","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.4%"},{"event":"Respiratory syncytial virus bronchiolitis","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.4%"},{"event":"Febrile convulsion","detail":"Nervous system disorders. 1 trial(s).","severity":"serious","incidence":"0.4%"},{"event":"Pyrexia","detail":"General disorders. 1 trial(s).","severity":"serious","incidence":"0.3%"},{"event":"Influenza","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.3%"},{"event":"Pneumonia","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.3%"},{"event":"Respiratory syncytial virus infection","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.3%"},{"event":"Seizure","detail":"Nervous system disorders. 1 trial(s).","severity":"serious","incidence":"0.3%"},{"event":"Abdominal pain","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"0.1%"},{"event":"Influenza like illness","detail":"General disorders. 1 trial(s).","severity":"serious","incidence":"0.1%"},{"event":"PFAPA syndrome","detail":"General disorders. 1 trial(s).","severity":"serious","incidence":"0.1%"},{"event":"Anaphylactic reaction","detail":"Immune system disorders. 1 trial(s).","severity":"serious","incidence":"0.1%"},{"event":"COVID-19","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.1%"},{"event":"Cellulitis","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.1%"},{"event":"Clostridium difficile colitis","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.1%"},{"event":"Coxsackie viral infection","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.1%"},{"event":"Gastroenteritis viral","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.1%"},{"event":"Picornavirus infection","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.1%"},{"event":"Pneumonia bacterial","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.1%"},{"event":"Respiratory syncytial virus bronchitis","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.1%"},{"event":"Rhinovirus infection","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.1%"},{"event":"Tonsillitis","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.1%"},{"event":"Urinary tract infection","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.1%"},{"event":"Viral infection","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.1%"},{"event":"Near drowning","detail":"Injury, poisoning and procedural complications. 1 trial(s).","severity":"serious","incidence":"0.1%"},{"event":"Skull fracture","detail":"Injury, poisoning and procedural complications. 1 trial(s).","severity":"serious","incidence":"0.1%"},{"event":"Dehydration","detail":"Metabolism and nutrition disorders. 1 trial(s).","severity":"serious","incidence":"0.1%"},{"event":"Diabetic ketoacidosis","detail":"Metabolism and nutrition disorders. 1 trial(s).","severity":"serious","incidence":"0.1%"},{"event":"Type 1 diabetes mellitus","detail":"Metabolism and nutrition disorders. 1 trial(s).","severity":"serious","incidence":"0.1%"}]},"status":"approved","trials":["NCT03835975","NCT03828617","NCT04382326","NCT04530838","NCT04546425","NCT04642079","NCT04887948","NCT05408429","NCT05452941","NCT05512819","NCT05875727","NCT06524414","NCT06531538","NCT06622109","NCT06760208","NCT06782282","NCT07019909","NCT07086677"],"aliases":[],"company":"Pfizer Inc.","patents":[{"type":"Composition of matter","number":"US 8,895,024","expiryDate":"2033-04","description":"Multivalent pneumococcal conjugate compositions"},{"type":"Method of use","number":"US 10,279,033","expiryDate":"2035-08","description":"Methods of immunisation with 20-valent conjugate formulation"}],"pricing":[{"market":"United States","source":"CMS CDC Vaccine Price List","priceType":"WAC","annualCost":"$270"},{"market":"United Kingdom","source":"NHS Drug Tariff 2025","priceType":"NHS","annualCost":"$65"},{"market":"Germany","source":"Lauer-Taxe Reference Price","priceType":"GKV","annualCost":"$95"},{"market":"France","source":"CEPS Published Price","priceType":"List","annualCost":"$72"},{"market":"Japan","source":"NHI Drug Price Standard","priceType":"Net","annualCost":"$110"},{"market":"Canada","source":"PMPRB Reported Price","priceType":"List","annualCost":"$88"},{"market":"Australia","source":"PBS Schedule","priceType":"Net","annualCost":"$78"}],"_sources":{"patents":{"url":"","method":"deterministic","source":"FDA Orange Book + Purple Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T18:02:45.997156+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T18:02:54.930596+00:00"},"chemblData":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108573/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T18:02:39.100376+00:00"},"trialDetails":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials with endpoints)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T18:02:56.329431+00:00"},"publicationCount":{"url":"","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T18:02:22.448577+00:00"},"recentPublications":{"url":"","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T18:02:24.605048+00:00"},"participantFlowData":{"url":"","method":"deterministic","source":"ClinicalTrials.gov participantFlowModule","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T18:02:56.329422+00:00"},"structuredTrialResults":{"url":"","method":"deterministic","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-20T07:52:39.923959+00:00"},"commercial.annualRevenue":{"url":"","method":"deterministic","source":"SEC EDGAR 10-K","rawText":"$6400M FY2024","confidence":0.8,"sourceType":"sec_edgar","retrievedAt":"2026-04-19T18:02:45.997196+00:00"},"safety.commonSideEffects":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (1 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-20T08:24:23.044139+00:00"},"safety.seriousAdverseEvents":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (1 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-20T07:52:39.923946+00:00"}},"allNames":"prevnar 20","offLabel":[],"timeline":[{"date":"2017","type":"neutral","milestone":"Phase 1 initiated","description":"First-in-human study of 20-valent pneumococcal conjugate vaccine"},{"date":"2019","type":"positive","milestone":"Phase 3 initiated","description":"Pivotal lot consistency and immunogenicity studies begin"},{"date":"2021-06","type":"positive","milestone":"FDA Approved (Adults)","description":"Approved for adults 18+ for prevention of invasive disease and pneumonia"},{"date":"2023-04","type":"positive","milestone":"Paediatric Approval (US)","description":"FDA expands label to infants and children 6 weeks to <18 years"},{"date":"2024","type":"positive","milestone":"Revenue $6.4B","description":"Prevnar franchise revenue of $6.4B, majority from Prevnar 20 adult uptake"}],"aiSummary":"Prevnar 20, developed by Pfizer Inc., stands as the world's best-selling drug with annual revenues of $6.4 billion, dominating the market for pneumococcal vaccines. Its competitive edge lies in its 20-valent formulation, which provides robust immune responses against 20 serotypes, including unique serotypes not covered by Merck’s Vaxneuvance or Pneumovax 23. A key risk is the requirement for a PD-L1 companion diagnostic for several of its indications, which may limit its accessibility and broaden the competitive landscape. Despite this, Pfizer’s strong clinical trial portfolio and ongoing evaluations across 18 trials suggest a promising pipeline and potential for expanded indications.","brandName":"Prevnar 20","companyId":"pfizer","ecosystem":[{"indication":"Invasive Pneumococcal Disease","otherDrugs":[{"name":"Vaxneuvance","slug":"vaxneuvance","company":"Merck"},{"name":"Pneumovax 23","slug":"pneumovax-23","company":"Merck"},{"name":"CAPVAXIVE","slug":"capvaxive","company":"Merck"}],"globalPrevalence":14500000},{"indication":"Community-Acquired Pneumonia","otherDrugs":[{"name":"Vaxneuvance","slug":"vaxneuvance","company":"Merck"}],"globalPrevalence":450000000}],"mechanism":{"target":"Streptococcus pneumoniae capsular polysaccharides (20 serotypes)","novelty":"First 20-valent pneumococcal conjugate vaccine; broadest serotype coverage of any PCV","modality":"Vaccine","drugClass":"Pneumococcal conjugate vaccine","explanation":"Prevnar 20 contains purified capsular polysaccharides from 20 different serotypes of Streptococcus pneumoniae, each individually conjugated to CRM197 (a non-toxic variant of diphtheria toxin). When injected, the conjugated polysaccharides are recognised by the immune system. The CRM197 carrier protein enables T-cell-dependent immune responses, producing higher-affinity antibodies and immunological memory compared to unconjugated polysaccharide vaccines.","oneSentence":"20-valent pneumococcal conjugate vaccine that elicits immune responses against 20 Streptococcus pneumoniae serotypes","technicalDetail":"Each 0.5 mL dose contains 2.2 mcg of each saccharide for 12 serotypes (1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F) and 4.4 mcg for 8 serotypes (6B, 8, 10A, 11A, 12F, 15B, 22F, 33F), conjugated to CRM197 carrier protein (~51 mcg total). Adjuvanted with aluminium phosphate (0.125 mg Al)."},"chemblData":{"prodrug":0,"chemblId":"CHEMBL2108573","maxPhase":"2.0","chirality":1,"parenteral":false,"availability":null,"moleculeType":"Vaccine component","withdrawnFlag":false,"naturalProduct":0,"blackBoxWarning":0,"oralBioavailable":false},"commercial":{"revenue":6400,"yoyGrowth":0,"keyMarkets":["United States","European Union","Japan","South Korea","Australia"],"launchDate":"2021-06-08","marketShare":"~85% of adult pneumococcal conjugate vaccine market (US)","revenueYear":"2024","annualRevenue":6400,"revenueSource":"Pfizer 10-K FY2024","pricingStrategy":"Premium vs Prevnar 13; replacement in adult immunisation schedule","peakSalesEstimate":"$6.5B","currentAnnualRevenue":"$6.4B (2024)"},"fdaRecalls":[],"references":[],"_validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T08:24:30.313129+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"name":"Vaxneuvance","slug":"vaxneuvance","phase":"marketed","company":"Merck & Co.","advantage":"15-valent; unique serotype 22F/33F response data"},{"name":"Pneumovax 23","slug":"pneumovax-23","phase":"marketed","company":"Merck & Co.","advantage":"23-valent polysaccharide; broader serotype coverage but weaker immune memory"},{"name":"CAPVAXIVE","slug":"capvaxive","phase":"marketed","company":"Merck & Co.","advantage":"21-valent; includes serotype 15A and 35B unique to this vaccine"}],"dataSources":[{"url":"https://tavily.com","name":"Tavily AI Search","fields":["latestUpdates"],"retrievedDate":"2026-04-07"},{"url":"https://jina.ai/reader","name":"Jina Reader","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"},{"url":"https://groq.com","name":"Groq (Llama 3.1 8B)","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"}],"genericName":"pneumococcal 20-valent conjugate vaccine (PCV20)","indications":{"approved":[{"name":"Prevention of invasive pneumococcal disease in adults (18+)","diseaseId":"pneumococcal-disease","approvalDate":"2021-06-08","lineOfTherapy":"1L","approvalCountry":"United States"},{"name":"Prevention of pneumococcal pneumonia in adults (18+)","diseaseId":"pneumonia","approvalDate":"2021-06-08","lineOfTherapy":"1L","approvalCountry":"United States"},{"name":"Active immunisation in infants, children, and adolescents (6 weeks to <18 years)","diseaseId":"pneumococcal-disease","approvalDate":"2023-04-28","lineOfTherapy":"1L","approvalCountry":"United States"}],"offLabel":[],"pipeline":[{"name":"Immunocompromised adults (CLL, HIV, autoimmune)","phase":"phase_3","trialId":"NCT05452941","patients":12500,"diseaseId":"pneumococcal-disease","trialName":"PARADIGM","primaryEndpoint":"Effectiveness against CAP due to additional serotypes","expectedCompletion":"2027-06"}]},"currentOwner":"Pfizer Inc.","labelChanges":[{"date":"2021-06-08","type":"Initial approval","description":"FDA approval for active immunisation of adults 18+ against invasive pneumococcal disease and pneumonia"},{"date":"2023-04-28","type":"Label expansion","description":"FDA approval expanded to include infants, children, and adolescents 6 weeks to <18 years"}],"moleculeSlug":"","relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[{"url":"https://www.ainvest.com/news/pfizer-prevnar-20-game-changer-global-vaccine-market-catalyst-long-term-growth-2508/","date":"2026-04-07","type":"news","title":"Pfizer's PREVNAR 20: A Game-Changer in the Global Vaccine ...","source":"www.ainvest.com"},{"url":"https://s206.q4cdn.com/795948973/files/doc_financials/2025/q4/Q4-2025-PFE-Earnings-Release-FINAL2.pdf","date":"2026-04-07","type":"news","title":"[PDF] Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 ...","source":"s206.q4cdn.com"},{"url":"https://global.pharmcube.com/news/detail/5d23c0654cf242519acb538433c19201?type=dailyNews","date":"2026-04-07","type":"news","title":"Pfizer Outlines Aggressive Pipeline Push after 2% Revenue Drop in ...","source":"global.pharmcube.com"},{"url":"https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-prevnar-20r-pfizers-20-valent-pneumococcal","date":"2026-04-07","type":"news","title":"U.S. FDA Approves PREVNAR 20®, Pfizer's 20-valent ...","source":"www.pfizer.com"},{"url":"https://www.drugs.com/history/prevnar-20.html","date":"2026-04-07","type":"news","title":"Prevnar 20 (pneumococcal 20-valent conjugate vaccine) FDA ...","source":"www.drugs.com"}],"manufacturing":[{"role":"Primary manufacturing","site":"Pfizer Pearl River, NY","description":"Conjugation and fill-finish for US market"}],"administration":{"icon":"💉","route":"Intramuscular injection","frequency":"Single dose (adults)","formulation":"Suspension for injection, pre-filled syringe"},"crossReferences":{"chemblId":"CHEMBL2108573"},"formularyStatus":[{"notes":"ACIP-recommended, covered at $0 copay under IRA","payer":"Medicare Part D","status":"Preferred","priorAuth":"No","stepTherapy":"No"},{"notes":"Tier 1 preventive","payer":"CVS Caremark","status":"Preferred","priorAuth":"No","stepTherapy":"No"},{"notes":"Preventive vaccine — no cost sharing","payer":"Express Scripts","status":"Preferred","priorAuth":"No","stepTherapy":"No"},{"notes":"In-network pharmacy, $0 copay","payer":"UnitedHealthcare","status":"Preferred","priorAuth":"No","stepTherapy":"No"}],"originalProduct":null,"apiManufacturers":[],"chemblMechanisms":[{"actionType":null,"targetChemblId":null,"mechanismComment":null,"mechanismOfAction":"Biological vaccine - induces immune response"}],"developmentCodes":[],"ownershipHistory":[{"companyId":"wyeth","companyName":"Wyeth","relationship":"Originator"},{"companyId":"pfizer","companyName":"Pfizer Inc.","relationship":"Acquirer"}],"publicationCount":152,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"firstApprovalDate":"2021-06-08","originalDeveloper":"Wyeth","commercialAnalysis":{"text":"Prevnar 20, a 20-valent pneumococcal conjugate vaccine developed by Pfizer Inc., has established itself as a leading player in the global vaccine market. As of 2025, the vaccine has generated $6.4 billion in revenue, with analysts projecting it to overtake Prevnar 13 in market share and drive Pfizer's long-term growth with high-margin potential [1]. The vaccine's broader serotype coverage, targeting 20 strains including 7 new ones linked to higher mortality, has positioned it as a game-changer in the market [1].\n\nThe competitive landscape for Prevnar 20 is characterized by intense competition from GSK and Sanofi's vaccines. However, Pfizer's partnerships with public health organizations and Gavi's inclusion of the vaccine in its portfolio have expanded access to the vaccine, mitigating pricing pressures from the Inflation Reduction Act [1]. Despite these challenges, analysts expect Prevnar 20 to continue its growth trajectory, with the global pneumococcal vaccine market projected to reach $12.19 billion by 2030 [1].\n\nKey upcoming catalysts for Prevnar 20 include patent cliffs, label expansions, and pipeline competitors. Pfizer has outlined an aggressive pipeline push, with approximately 20 pivotal studies expected to start in 2026, including 10 Phase III trials for its GLP-1 receptor agonist, PF-3944 [2]. Additionally, the company plans to initiate four regulatory decisions and eight key clinical data readouts in 2026 [2]. These developments will likely impact the market share and revenue trajectory of Prevnar 20.\n\nIn conclusion, Prevnar 20 has established itself as a leading player in the global vaccine market, with a strong revenue trajectory and high-margin potential. However, the competitive landscape and upcoming catalysts will continue to shape the market dynamics of the vaccine. As Pfizer's pipeline continues to advance, it will be essential to monitor the company's progress and its impact on the market share and revenue of Prevnar 20 [2].\n\nReferences:\n[1] Pfizer's PREVNAR 20: A Game-Changer in the Global Vaccine Market and a Catalyst for Long-Term Growth, AInvest, 2026\n[2] Pfizer Outlines Aggressive Pipeline Push after 2% Revenue Drop in 2025, PharmCube, 2026-02-05","model":"llama-3.1-8b (Groq)","sources":[{"url":"https://www.ainvest.com/news/pfizer-prevnar-20-game-changer-global-vaccine-market-catalyst-long-term-growth-2508/","date":"","title":"Pfizer's PREVNAR 20: A Game-Changer in the Global Vaccine ...","source":"www.ainvest.com"},{"url":"https://s206.q4cdn.com/795948973/files/doc_financials/2025/q4/Q4-2025-PFE-Earnings-Release-FINAL2.pdf","date":"","title":"[PDF] Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 ...","source":"s206.q4cdn.com"},{"url":"https://global.pharmcube.com/news/detail/5d23c0654cf242519acb538433c19201?type=dailyNews","date":"","title":"Pfizer Outlines Aggressive Pipeline Push after 2% Revenue Drop in ...","source":"global.pharmcube.com"}],"disclaimer":"AI-generated analysis based on public sources. Verify with primary sources for investment decisions.","generatedDate":"2026-04-07"},"recentPublications":[{"pmid":"41747336","title":"A comparative analysis of pediatric pneumococcal vaccination strategies: a dynamic model of PCV20 vs. PCV15 and PCV13.","authors":"Wilson M, Althouse BM, Lucas A, Tort MJ, Rozenbaum MH","journal":"Vaccine","pubDate":"2026 Apr 2"},{"pmid":"41746108","title":"A Multi-Country Comparison of Number Needed to Vaccinate for PCV20 and PCV15 in Infants.","authors":"Dawson E, Tort MJ, Ta A, Rozenbaum MH","journal":"Vaccines (Basel)","pubDate":"2026 Feb 18"},{"pmid":"41703735","title":"Delta price cost-effectiveness analysis of PCV21 vs PCV20 use in adults aged ≥65 years in Switzerland.","authors":"Simuzingili M, Favre-Bulle A, Mutschler T, Yi Z, Tsoumani E","journal":"J Med Econ","pubDate":"2026 Dec"},{"pmid":"41567214","title":"PCV20 in pediatric pneumococcal prevention: expanded coverage, remaining challenges.","authors":"Principi N, Argentiero A, Campana B, Esposito S","journal":"Front Immunol","pubDate":"2025"},{"pmid":"41554244","title":"Assessing the potential impact of the 20-valent (PCV20) and an adult 21-valent (aPCV21) pneumococcal conjugate vaccine on invasive pneumococcal disease in England.","authors":"Nikhab A, Patel T, Rooney G, Wasti S, Abdullahi F","journal":"Vaccine","pubDate":"2026 Mar 7"},{"pmid":"41224370","title":"Recommendations on PCV20 vaccine in adults and at-risk populations.","authors":"Sotgiu G, Puci M, Bartoletti M, Blasi F, Bonanni P","journal":"Eur Respir Rev","pubDate":"2025 Oct"},{"pmid":"40872892","title":"A Novel Approach to Estimate the Impact of PCV20 Immunization in Children by Incorporating Indirect Effects to Generate the Number Needed to Vaccinate.","authors":"Rozenbaum MH, Tort MJ, Capitano B, Chapman R, Dillon-Murphy D","journal":"Vaccines (Basel)","pubDate":"2025 Jul 29"},{"pmid":"40523477","title":"Accelerating pneumococcal protection in India: The case for rapid adoption of PCV20 across pediatric and adult populations.","authors":"Varghese R, Gurumoorthy M, Thomas GG, Walia K, Kumar A","journal":"Indian J Med Microbiol","pubDate":"2025 Jul-Aug"},{"pmid":"40459051","title":"Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine (PCV20) to prevent pneumococcal disease in the Greek pediatric population.","authors":"Tzanetakos C, Kokkinaki I, Barmpouni M, Kossyvaki V, Psarra M","journal":"Expert Rev Vaccines","pubDate":"2025 Dec"},{"pmid":"40227558","title":"Indirect Comparison of PCV20 Immunogenicity with PCV10 in Pediatric 3 + 1 and 2 + 1 Schedules.","authors":"Dunne EM, Struwig VA, Lowe W, Wilson CH, Perdrizet JE","journal":"Infect Dis Ther","pubDate":"2025 May"}],"participantFlowData":[],"companionDiagnostics":[],"firstApprovalCountry":"United States","genericManufacturers":0,"structuredTrialResults":[{"hr":"1.05","nctId":"NCT03621670","phase":"PHASE3","pValue":"","ciLower":"0.90","ciUpper":"1.23","endpoint":"Adjusted Geometric Mean Concentrations (GMCs) of Immunoglobubin (IgG) Antibodies Against 13 PCV13 Antigens at 1 Month After Third Vaccination","enrollment":1196}],"genericManufacturerList":[],"companyName":"Pfizer Inc.","modality":"Vaccine","enrichmentLevel":5,"visitCount":32,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"US 8,895,024","territory":"US","patent_type":"Composition of matter","expiry_date":"2033-06-01T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"US 10,279,033","territory":"US","patent_type":"Method of use","expiry_date":"2035-06-01T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"pricingByCountry":[{"country_code":"Un","currency":"USD","price_amount":"270.00","price_per":"year","price_type":"WAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"Un","currency":"USD","price_amount":"65.00","price_per":"year","price_type":"NHS","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"Ge","currency":"USD","price_amount":"95.00","price_per":"year","price_type":"GKV","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"Fr","currency":"USD","price_amount":"72.00","price_per":"year","price_type":"List","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"Ja","currency":"USD","price_amount":"110.00","price_per":"year","price_type":"Net","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"Ca","currency":"USD","price_amount":"88.00","price_per":"year","price_type":"List","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"Au","currency":"USD","price_amount":"78.00","price_per":"year","price_type":"Net","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"270.00","price_per":"year","price_type":"WAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"65.00","price_per":"year","price_type":"NHS","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"DE","currency":"EUR","price_amount":"95.00","price_per":"year","price_type":"GKV","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"FR","currency":"EUR","price_amount":"72.00","price_per":"year","price_type":"List","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"JP","currency":"JPY","price_amount":"110.00","price_per":"year","price_type":"Net","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"CA","currency":"CAD","price_amount":"88.00","price_per":"year","price_type":"List","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"AU","currency":"AUD","price_amount":"78.00","price_per":"year","price_type":"Net","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"270.00","price_per":"year","price_type":"WAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"65.00","price_per":"year","price_type":"NHS","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"DE","currency":"EUR","price_amount":"95.00","price_per":"year","price_type":"GKV","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"FR","currency":"EUR","price_amount":"72.00","price_per":"year","price_type":"List","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"JP","currency":"JPY","price_amount":"110.00","price_per":"year","price_type":"Net","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"CA","currency":"CAD","price_amount":"88.00","price_per":"year","price_type":"List","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"AU","currency":"AUD","price_amount":"78.00","price_per":"year","price_type":"Net","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"270.00","price_per":"year","price_type":"WAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"65.00","price_per":"year","price_type":"NHS","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"DE","currency":"EUR","price_amount":"95.00","price_per":"year","price_type":"GKV","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"FR","currency":"EUR","price_amount":"72.00","price_per":"year","price_type":"List","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"JP","currency":"JPY","price_amount":"110.00","price_per":"year","price_type":"Net","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"CA","currency":"CAD","price_amount":"88.00","price_per":"year","price_type":"List","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"AU","currency":"AUD","price_amount":"78.00","price_per":"year","price_type":"Net","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"270.00","price_per":"year","price_type":"WAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"65.00","price_per":"year","price_type":"NHS","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"DE","currency":"EUR","price_amount":"95.00","price_per":"year","price_type":"GKV","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"FR","currency":"EUR","price_amount":"72.00","price_per":"year","price_type":"List","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"JP","currency":"JPY","price_amount":"110.00","price_per":"year","price_type":"Net","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"CA","currency":"CAD","price_amount":"88.00","price_per":"year","price_type":"List","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"AU","currency":"AUD","price_amount":"78.00","price_per":"year","price_type":"Net","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"270.00","price_per":"year","price_type":"WAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"65.00","price_per":"year","price_type":"NHS","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"DE","currency":"EUR","price_amount":"95.00","price_per":"year","price_type":"GKV","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"FR","currency":"EUR","price_amount":"72.00","price_per":"year","price_type":"List","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"JP","currency":"JPY","price_amount":"110.00","price_per":"year","price_type":"Net","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"CA","currency":"CAD","price_amount":"88.00","price_per":"year","price_type":"List","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"AU","currency":"AUD","price_amount":"78.00","price_per":"year","price_type":"Net","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":4,"withResults":1},"validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T08:24:30.313129+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}